Ianalumab: all 33 studies that test it

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.Not yet recruitingNCT07660172Phase 2
• Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenRecruitingNCT07621809Phase 3
• A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)RecruitingNCT07421167Phase 2
• Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)RecruitingNCT06711887Phase 3
• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).RecruitingNCT06133972Phase 3
• Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedNCT03827798Phase 2Results posted
• Study the Efficacy and Safety of VAY736 and CFZ533 in SLE PatientsCompletedNCT03656562Phase 2Results posted
• VAY736 in Combination With Ibrutinib in Patients With CLL on IbrutinibTerminatedNCT03400176Phase 1Results posted
• Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary FibrosisTerminatedNCT03287414Phase 2Results posted
• Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)CompletedNCT02962895Phase 2Results posted
• PD of VAY736 in Patients With Primary Sjögren's SyndromeCompletedNCT02149420Phase 2Results posted
• A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT02038049Phase 2Results posted
• Study of Efficacy and Safety of VAY736 in Patients With Pemphigus VulgarisTerminatedNCT01930175Phase 2Results posted
• Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabWithdrawnNCT07039422Phase 2
• A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisActive, not recruitingNCT06470048Phase 2
• Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune DiseasesWithdrawnNCT06411639Phase 1
• Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseActive, not recruitingNCT06293365Phase 2
• A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.Active, not recruitingNCT05985915Phase 3
• A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of TherapiesActive, not recruitingNCT05885555Phase 2
• Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)Active, not recruitingNCT05653349Phase 3
• A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed SteroidsActive, not recruitingNCT05653219Phase 3
• A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaActive, not recruitingNCT05648968Phase 3
• Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Active, not recruitingNCT05639114Phase 3
• Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Active, not recruitingNCT05624749Phase 3
• Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeCompletedNCT05350072Phase 3
• Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeActive, not recruitingNCT05349214Phase 3
• Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisActive, not recruitingNCT05126277Phase 3
• Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.CompletedNCT05124925Phase 2
• Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid ArthritisCompletedNCT03574545Phase 1
• ADCC Mediated B-Cell dEpletion and BAFF-R BlockadeCompletedNCT03217422Phase 2/3
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis PatientsCompletedNCT02675803Phase 1
• Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's SyndromeWithdrawnNCT02495129Phase 1/2
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL PatientsTerminatedNCT02137889Phase 1

← Ianalumab overview